Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BVRS-GamVac MERS Vaccine in Healthy Volunteers
NCT04130594Phase 2Unknown
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BVRS-GamVac in Middle East respiratory syndrome (MERS) (4 arms). Primary endpoints: Number of Participants With Adverse Events at 180 days, Number of Participants With Serious Adverse Events at 180 days and 2 more. Status: unknown.
02
Drugs
BVRS-GamVac
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT04130594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130594.